4-Isopropyloxy-benzamidoxim | 90873-16-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-Isopropyloxy-benzamidoxim
• 英文别名: N'-hydroxy-4-propan-2-yloxybenzenecarboximidamide
• CAS: 90873-16-8
• 化学式: C₁₀H₁₄N₂O₂
• 分子量: 194.233
• InChiKey: BSHLSFXGNXGTJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Isopropyloxy-benzamidoxim 在 sodium methylate 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 1-(3-(5-amino-4-(3-(4-isopropoxyphenyl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-yl)phenyl)ethan-1-one oxime
  参考文献：
  名称：

  Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan

  摘要：

  Chemical probes of microRNA (miRNA) function are potential tools for understanding miRNA biology that also provide new approaches for discovering therapeutics for miRNA-associated diseases. MicroRNA-21 (miR-21) is an oncogenic miRNA that is overexpressed in most cancers and has been strongly associated with driving chemoresistance in cancers such as renal cell carcinoma (RCC). Using a cell-based luciferase reporter assay to screen small molecules, we identified a novel inhibitor of miR-21 function. Following structure-activity relationship studies, an optimized lead compound demonstrated cytotoxicity in several cancer cell lines. In a chemoresistant-RCC cell line, inhibition of miR-21 via small molecule treatment rescued the expression of tumor-suppressor proteins and sensitized cells to topotecan-induced apoptosis. This resulted in a > 10-fold improvement in topotecan activity in cell viability and clonogenic assays. Overall, this work reports a novel small molecule inhibitor for perturbing miR-21 function and demonstrates an approach to enhancing the potency of chemotherapeutics specifically for cancers derived from oncomir addiction.

  DOI：

  10.1021/acs.jmedchem.7b01891
• 作为产物：
  描述：

  4-异丙氧基苯甲腈 在 盐酸羟胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 生成 4-Isopropyloxy-benzamidoxim
  参考文献：
  名称：

  Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan

  摘要：

  Chemical probes of microRNA (miRNA) function are potential tools for understanding miRNA biology that also provide new approaches for discovering therapeutics for miRNA-associated diseases. MicroRNA-21 (miR-21) is an oncogenic miRNA that is overexpressed in most cancers and has been strongly associated with driving chemoresistance in cancers such as renal cell carcinoma (RCC). Using a cell-based luciferase reporter assay to screen small molecules, we identified a novel inhibitor of miR-21 function. Following structure-activity relationship studies, an optimized lead compound demonstrated cytotoxicity in several cancer cell lines. In a chemoresistant-RCC cell line, inhibition of miR-21 via small molecule treatment rescued the expression of tumor-suppressor proteins and sensitized cells to topotecan-induced apoptosis. This resulted in a > 10-fold improvement in topotecan activity in cell viability and clonogenic assays. Overall, this work reports a novel small molecule inhibitor for perturbing miR-21 function and demonstrates an approach to enhancing the potency of chemotherapeutics specifically for cancers derived from oncomir addiction.

  DOI：

  10.1021/acs.jmedchem.7b01891

文献信息

• [EN] NOVEL OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS INÉDITS D'OXADIAZOLE
  申请人：ABBOTT LAB

  公开号：WO2011071570A1

  公开（公告）日：2011-06-16

  Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

  新型噁二唑化合物，含有这种化合物的药物组合物以及将这些化合物或组合物用作治疗与调节S1P家族G蛋白偶联受体活性相关的疾病的激动剂或拮抗剂的用途被披露，特别是通过提供有益的免疫抑制作用。
• QUINOLINE DERIVATIVES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES AND DISORDERS
  申请人：Dahl Russell

  公开号：US20170151225A1

  公开（公告）日：2017-06-01

  Provided herein are quinolines, e.g., a compound of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caused disease. Also provided herein are methods of their use for reducing endoplasmic reticulum stress and modulating the activity of a sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase.

  本文提供了喹啉化合物，例如式I的化合物，其药物组成物以及使用它们治疗、预防或缓解一种或多种内质网应激引起的疾病症状的方法。本文还提供了使用它们减少内质网应激和调节肌浆/内质网Ca2+ATP酶活性的方法。
• Pentamidin-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel
  申请人：Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG

  公开号：EP2550963A1

  公开（公告）日：2013-01-30

  Die vorliegende Erfindung betrifft Prodrug-Derivate des Pentamidins, ihre Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere Tumorerkrankungen, sowie der Leishmaniose, Trypanosomiasis, der Pneumocystis carinii Pneumonie (PcP), sowie der Malaria.

  本发明涉及喷他脒的原药衍生物，其用途是治疗和/或预防疾病，特别是肿瘤疾病，以及利什曼病、锥虫病、卡氏肺囊虫肺炎（PcP）和疟疾。
• NOVEL OXADIAZOLE COMPOUNDS
  申请人：Abbott Laboratories

  公开号：EP2509424A1

  公开（公告）日：2012-10-17
• [DE] PENTAMIDIN-AMIDOXIMSÄUREESTERS ALS PRODRUGS UND IHRE VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] PENTAMIDINE AMIDOXIME ACID ESTERS AS PRODRUGS AND USE THEREOF AS DRUGS<br/>[FR] PENTAMIDINE-AMIDOXIME-ESTER D'ACIDE SERVANT DE PROMÉDICAMENTS ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
  申请人：DRITTE PATENTPORTFOLIO BETEILI

  公开号：WO2013014059A1

  公开（公告）日：2013-01-31

  Die vorliegende Erfindung betrifft Prodrug-Derivate des Pentamidins, ihre Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere Tumorerkrankungen, sowie der Leishmaniose, Trypanosomiasis, der Pneumocystis carinii Pneumonie (PcP), sowie der Malaria.